Displaying 1141 - 1160 of 1904
FTC and Justice Department Officials Meet with Officials of Chinese Antitrust Agencies
FTC, DOJ Issue Joint Statement on Preserving Competition in the Defense Industry
Endo Pharmaceuticals / Impax Labs
The FTC filed a complaint in federal district court alleging that Endo Pharmaceuticals Inc. and several other drug companies violated antitrust laws by using pay-for-delay settlements to block consumers’ access to lower-cost generic versions of Opana ER and Lidoderm with an agreement not to market an authorized generic – often called a “no-AG commitment” – as a form of reverse payment. The complaint, filed in the Eastern District of Pennsylvania, alleges that Endo paid the first generic companies that filed for FDA approval – Impax Laboratories, Inc. and Watson Laboratories, Inc. – to eliminate the risk of competition for Opana ER and Lidoderm, in violation of the Federal Trade Commission Act. Opana ER is an extendedrelease opioid used to relieve moderate to severe pain. Lidoderm is a topical patch used to relieve pain associated with post-herpetic neuralgia, a complication of shingles. The FTC is seeking a court judgment declaring that the defendants’ conduct violates the antitrust laws, ordering the companies to disgorge their ill-gotten gains, and permanently barring them from engaging in similar anticompetitive behavior in the future. Teikoko Pharma USA and Teikoku Seiyaku Co., Ltd. agreed to a stipulated order resolving FTC charges.
In November 2016, the FTC voluntarily dismissed the complaint in this action. On January 23, 2017, the FTC refiled charges related to the Lidoderm agreements in federal court in California (Federal Trade Commission vs. Allergan plc; Watson Laboratories, Inc., et al) and refiled charges related to the Opana ER agreement in a Part 3 administrative proceeding. (In re Impax Laboratories, Inc.)
FTC Approves Modification of Final Order Related to Pfizer’s 2009 Acquisition of Wyeth
FTC Chairwoman Releases 2015 Annual Highlights
FTC Approves Modified Final Order for Hikma Pharmaceuticals PLC
FTC Sues Endo Pharmaceuticals Inc. and Others for Illegally Blocking Lower-Cost Generic Versions of the Branded Drugs Opana ER and Lidoderm
FTC Staff Comment: Alaska Legislature Should Consider Potential Benefits to Consumers of Expanding Access to Telehealth Services
FTC Staff Comment: Kentucky Legislature Should Consider Potential Benefits to Consumers of Enhanced Competition Among Denture Providers
Statement of FTC Chairwoman Edith Ramirez on the U.S. Supreme Court's Decision in McWane Inc. v. FTC
FTC Approves Final Order Preserving Competition Among Outpatient Dialysis Clinics in Laredo, Texas
FTC Amicus Brief Urges Appeals Court to Correct Legal Errors in District Court’s Antitrust Analysis of Reverse-Payment Agreement
FTC Chairwoman Ramirez Testifies Before Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights
FTC Puts Conditions on Drug Manufacturer Hikma Pharmaceuticals PLC’s Proposed Acquisition of Roxane Laboratories Inc. and Boehringer Ingelheim Roxane, Inc. from Boehringer Ingelheim Corporation
FTC Approves Modified Consent Order for Mylan N.V.
FTC Requires Drug Marketer Hikma Pharmaceuticals PLC to Divest Rights to Five Generic Injectable Drugs as a Condition of Acquiring Certain Drug Products from Ben Venue Laboratories, Inc.
FTC Puts Conditions on Generic Drug Marketer Lupin Ltd.’s Proposed Acquisition of Gavis Pharmaceuticals LLC
FTC Amicus Brief Urges Appeals Court to Correct District Court Holding that Proving Injury-in-Fact Is Necessary to Establish an Antitrust Violation
FTC Submits Fiscal Year 2017 Budget Request, Performance Plan, and Fiscal Year 2015 Performance Report to Congress
Displaying 1141 - 1160 of 1904